在线血液透析滤过与高通量血液透析的真实世界住院结局比较:一项回顾性国际队列研究
该回顾性国际队列纳入2019至2022年欧洲、中东和非洲Fresenius Medical Care NephroCare中心的71,669例透析患者,45%接受高通量血液透析、55%接受在线血液透析滤过(HDF)。经负二项回归及逆概率加权调整后,HDF组全因住院发生率(调整IRR 0.80,95%CI 0.79–0.82)和住院天数(调整IRR 0.80,95%CI 0.78–0.82)均低于高通量血液透析组,且在不同亚组及多数主要住院病因中结果一致。
要点
- 在线高通量HDF与全因住院发生率降低相关(调整IRR 0.80,95%CI 0.79–0.82)。
- 在线高通量HDF与住院天数减少相关(调整IRR 0.80,95%CI 0.78–0.82)。
- 住院减少在心血管病、感染及液体相关并发症等主要病因中基本一致。
核心结论
- 在多区域真实世界队列中,在线高通量HDF较高通量血液透析显著降低住院发生率和住院天数。
- 结果提示在线高通量HDF可能有助于降低ESKD患者的疾病负担。
研究设计与样本
- 回顾性国际队列研究,数据来自欧洲、中东和非洲Fresenius Medical Care NephroCare中心的欧洲临床数据库。
- 纳入2019年1月至2022年12月接受中心透析的71,669例患者,45%接受高通量血液透析、55%接受HDF。
- 采用负二项回归估计住院结局的发病率比(IRR),并以逆概率治疗加权调整组间基线差异。
主要发现
- HDF组共接受12,741,453次HDF治疗,平均对流剂量25.8 L,84%的治疗对流剂量≥23 L。
- 与高通量血液透析相比,HDF组全因住院调整IRR为0.80(95%CI 0.79–0.82)。
- 与高通量血液透析相比,HDF组住院天数调整IRR为0.80(95%CI 0.78–0.82)。
- 住院减少在分析的各亚组及多数主要住院病因中保持一致,包括心血管病、感染和液体相关并发症。
临床怎么用
- 对于符合条件的ESKD透析患者,在线高通量HDF可作为高通量血液透析的替代模式以降低住院风险。
- 临床决策需结合患者对流剂量的耐受性及中心HDF技术条件综合评估。
局限性
- 为回顾性观察性研究,尽管采用逆概率治疗加权调整,仍可能存在残余混杂。
- 研究仅纳入Fresenius Medical Care NephroCare中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Compared with high-flux hemodialysis, postdilution high volume hemodiafiltration was associated with a lower number of hospital admissions. Compared with high-flux hemodialysis, postdilution high volume hemodiafiltration was associated with reduced days spent in the hospital. BACKGROUND: Patients with ESKD undergoing hemodialysis experience high rates of hospitalizations and mortality, partly due to the incomplete removal of some toxic uremic molecules. To improve outcomes, multiple modalities of kidney replacement therapy have been developed, including high-flux hemodialysis and on-line hemodiafiltration (HDF). Notably, on-line high-volume HDF (HV-HDF) has demonstrated mortality benefits over high-flux hemodialysis in some randomized trials. METHODS: This retrospective cohort study evaluated hospitalization outcomes among in-center dialysis patients treated with HV-HDF and high-flux hemodialysis at Fresenius Medical Care NephroCare centers across Europe, the Middle East, and Africa between January 2019 and December 2022. Data were extracted from the European Clinical Database. The primary outcome was all-cause hospitalization; secondary outcomes included cause-specific hospitalizations. Negative binomial regression was used to estimate incidence rate ratios (IRRs) for hospital outcomes, incorporating inverse probability of treatment weighting to adjust for baseline differences between treatment groups. RESULTS: A total of 71,669 patients were included, with 45% receiving hemodialysis and 55% receiving HDF. During the follow-up period, patients in the HDF group underwent a total of 12,741,453 HDF treatments, with a mean convection volume of 25.8 L (84% with CV≥23L). Compared with hemodialysis, treatment with HDF was associated with a lower incidence of both hospital admissions (adjusted IRR, 0.80; 95% confidence interval, 0.79 to 0.82) and days spent in the hospital (adjusted IRR, 0.80; 95% confidence interval, 0.78 to 0.82). These reductions were consistent across subgroups analyzed and across most major causes of hospitalization, including cardiovascular disease, infections, and fluid-related complications. CONCLUSIONS: In this large, real-world cohort spanning multiple regions and dialysis centers, HV-HDF was associated with significantly lower rates of both hospital admissions and days spent in the hospital compared with treatment with high-flux hemodialysis. These findings suggest that HV-HDF may have the potential to reduce morbidity in patients with ESKD.
引用
- Zhang Y, Winter A, Ficociello LH, et al. Real-World Hospitalization Outcomes with On-Line Hemodiafiltration Versus High-Flux Hemodialysis: A Retrospective, International Cohort Study. Clin J Am Soc Nephrol. 2025. PMID: 41433104. doi:10.2215/CJN.0000000955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。